drugset / Trial / NCT00003293

SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme

NCT00003293

Phase 3 Completed Pfizer
RandomizedTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether SU-101 is more effective than procarbazine in treating patients with glioblastoma multiforme. PURPOSE: Randomized phase III trial to compare the effectiveness of SU-101 with that of procarbazine in treating patients with glioblastoma multiforme that has recurred.

Timeline

Start
1998-02
Primary completion
2001-05
Completion
2001-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Leflunomide Small molecule Intravenous
Subject procarbazine Small molecule Oral